交易中 05-18 10:08:03 美东时间
-0.120
-0.84%
ADAR1 Capital Management reports Rallybio common share purchase worth $1.1 million ADAR1 Capital Management, a 10% owner of Rallybio, reported additional purchases of common stock, lifting its stake to 910,143 shares. Buying prices disclosed in the filing ranged from $13.8 to $14 per share. The posi
05-16 08:50
ADAR1 Capital Management acquires Rallybio common shares worth $2,183,857.51 ADAR1 Capital Management, a 10% owner of Rallybio (RLYB), raised its stake to 779,784 shares through open-market purchases. Shares were bought at weighted average prices of USD 13.9, USD 13.97, USD 14. Filing was made joint
05-07 09:33
Rallybio initial beneficial ownership filing shows ADAR1 Capital Management stake of 623,879 shares Rallybio Form 3 filing shows ADAR1 Capital Management reporting 623,879 shares of common stock held indirectly. Filing lists ADAR1 Capital Management as a 10% owner, with Daniel Schneeberger also repo
05-07 09:31
Rallybio ( ($RLYB) ) has issued an announcement. On March 1, 2026, Rallybio Cor...
05-04 20:17
Rallybio says Candid terminates merger agreement, owes $50 million fee Candid Therapeutics terminated its merger agreement with Rallybio on May 3, 2026, alongside signing a permitted alternative deal with UCB. Termination triggers a USD 50 million parent termination fee payable to Rallybio. Parties
05-04 19:55
eBay (NASDAQ: EBAY) rose sharply after GameStop (NYSE: GME) proposed to acquire it for $125/share, valuing GME at $55.5B. eBay shares jumped 8.1% to $112.50 in pre-market trading.
05-04 16:57
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
04-07 02:38
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
03-03 04:56
Rallybio stock jumps after announcing a $505 million merger with Candid Therapeutics, boosting cash to $700 million.
03-02 23:51
Following closing, pre-Transaction Rallybio equityholders are expected to own approximately 3.65% of the combined company, and pre-Transaction Candid equityholders (inclusive of investors participating in the Financing)
03-02 21:09